FERRARI RENEWS ITS PARTNERSHIP WITH PHILIP MORRIS INTERNATIONAL

12/3/25 6:19:09 AM ET

$PM

$RACE

Medicinal Chemicals and Botanical Products

Health Care

Auto Manufacturing

Industrials

Get the next $PM alert in real time by email

Maranello (Italy), December 3, 2025 – Ferrari N.V. (NYSE/EXM: RACE) ("Ferrari" or "the Company") announced today that Ferrari S.p.A., its wholly-owned Italian subsidiary, has renewed and strengthened its multi-year partnership with Philip Morris International (NYSE:PM).

Under the agreement – signed today and taking effect on January 1, 2026 – Philip Morris International becomes a Premium Partner of Scuderia Ferrari HP and a Series Partner of the Ferrari Challenge Trofeo Pirelli, continuing a collaboration that has spanned more than 50 years.

For further information:

Media Relations

tel.: +39 0536 949337

Email: [email protected]

Attachment

CS_FNV_PMI_ENG

Get the next $PM alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$PM
$RACE

Company	Date	Price Target	Rating	Analyst
Ferrari N.V. $RACE	2/12/2026		Sell → Neutral	Citigroup
Philip Morris International Inc $PM	1/20/2026	$180.00	Buy → Hold	Jefferies
Ferrari N.V. $RACE	1/13/2026		Buy → Hold	HSBC Securities
Ferrari N.V. $RACE	12/8/2025	$425.00	Overweight → Equal-Weight	Morgan Stanley
Ferrari N.V. $RACE	10/2/2025	$470.00	Hold → Buy	HSBC Securities
Ferrari N.V. $RACE	9/16/2025		Buy	Berenberg
Ferrari N.V. $RACE	9/2/2025		Hold → Buy	Deutsche Bank
Philip Morris International Inc $PM	7/9/2025	$220.00	Buy	Jefferies

More analyst ratings

$PM
$RACE
Press Releases

Fastest customizable press release news feed in the world

View All

FERRARI RELEASES ITS 2025 ANNUAL REPORT AND FILES ANNUAL REPORT ON FORM 20-F

Maranello (Italy), February 19, 2026 - Ferrari N.V. (NYSE/EXM: RACE) announced today that it has published its 2025 Annual Report and filed with the United States Securities and Exchange Commission its annual report on Form 20-F, including financial statements for the fiscal year ended December 31, 2025. The 2025 Sustainability Statement, prepared in accordance with the requirements from the European Sustainability Reporting Standard (ESRS) on a voluntary basis, is included in the 2025 Annual Report. Ferrari's 2025 Annual Report and annual report on Form 20-F are available under section Investors on Ferrari's corporate website at https://www.ferrari.com/en-EN/corporate, where they can be vi

2/19/26 12:44:14 PM ET

$RACE

Auto Manufacturing

Industrials

DIVIDEND DISTRIBUTION PROPOSAL

Maranello (Italy), February 19, 2026 - Ferrari N.V. (NYSE/EXM: RACE) (the "Company") announced today that its Board of Directors intends to recommend to the Company's shareholders a dividend distribution to the holders of common shares of Euro 3.615 per common share, with an increase of approximately 21% compared to the prior year and corresponding to a total distribution of approximately Euro 640 million. The distribution will be subject to its approval by the Annual General Meeting of Shareholders which is scheduled to be held on April 15, 2026. If shareholders approve the proposed dividend distribution, the ex-date is expected to be April 20, 2026 on EXM and April 21, 2026 on NYSE, the

2/19/26 12:20:10 PM ET

$RACE

Auto Manufacturing

Industrials

Philip Morris International Presents at 2026 CAGNY Conference; Reaffirms 2026 Full-Year Forecast

Regulatory News: Philip Morris International Inc.'s (PMI) (NYSE:PM) Group CEO PMI, Jacek Olczak, and Group Chief Financial Officer, Emmanuel Babeau, will address investors today at the 2026 Consumer Analyst Group of New York (CAGNY) Conference at approximately 10:00 a.m. ET. The live webcast and presentation slides will be available here. The webcast replay will be available at the same link for six months after the event. The webcast may also be accessed on mobile devices by downloading PMI's Investor Relations App at www.pmi.com/irapp. The presentation will cover: How a transformed PMI is leading the industry in an evolving operating environment; The success and future opportu

2/18/26 7:00:00 AM ET

$PM

Medicinal Chemicals and Botanical Products

Health Care

$PM
$RACE
Financials

Live finance-specific insights

View All

DIVIDEND DISTRIBUTION PROPOSAL

2/19/26 12:20:10 PM ET

$RACE

Auto Manufacturing

Industrials

Philip Morris International Presents at 2026 CAGNY Conference; Reaffirms 2026 Full-Year Forecast

2/18/26 7:00:00 AM ET

$PM

Medicinal Chemicals and Botanical Products

Health Care

Philip Morris International Reports 2025 Fourth-Quarter & Full-Year Results

Delivers Full Year 2025 Reported Diluted EPS of $7.26 compared to $4.52 in 2024 and Adjusted Diluted EPS of $7.54, Representing Growth of 14.8%, and 14.2% on a Currency-Neutral Basis; Provides 2026 - 2028 Growth Targets Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 fourth quarter results.1 "We achieved another remarkable year of results in 2025, with a fifth consecutive year of volume growth, net revenues surpassing $40 billion, including close to $17 billion from our smoke-free business, and very good operating margin expansion," said Jacek Olczak, Group CEO PMI. "With excellent results in 2024 and 2025, we have delivered our three-year CA

2/6/26 6:59:00 AM ET

$PM

Medicinal Chemicals and Botanical Products

Health Care

$PM
$RACE
Leadership Updates

Live Leadership Updates

View All

Philip Morris International Opens Dialogue on the Future of Human Cognition as a Defining Frontier in the Age of AI

The paper calls for global debate to ensure AI enhances—rather than diminishes—uniquely human strengths in an increasingly automated world Philip Morris International Inc. (NYSE:PM) today released a new white paper, "Human Cognition: The Next Frontier?", inviting leaders across business, policy, and academia to join a global conversation on the evolving role of human cognition as artificial intelligence transforms work, society, and the economy. The white paper explores how human capabilities such as - critical thinking, creativity and adaptability - are poised to become the "superskill" of the future, driving progress in an era of human-machine collaboration. As AI automates routine ta

1/20/26 5:03:00 AM ET

$PM

Medicinal Chemicals and Botanical Products

Health Care

Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation

Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex

9/17/24 9:11:00 AM ET

$PM

Medicinal Chemicals and Botanical Products

Health Care

Philip Morris International Names New External Affairs Leader

Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company's CEO, Jacek Olczak. "Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products," said CEO Jacek Olczak. "He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I'm looking forward to working with Christos and excited to see what

3/26/24 5:48:00 AM ET

$PM

Medicinal Chemicals and Botanical Products

Health Care

FERRARI RENEWS ITS PARTNERSHIP WITH PHILIP MORRIS INTERNATIONAL

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$PM
$RACE

FERRARI RENEWS ITS PARTNERSHIP WITH PHILIP MORRIS INTERNATIONAL

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$PM
$RACE

$PM
$RACE
Press Releases

FERRARI RELEASES ITS 2025 ANNUAL REPORT AND FILES ANNUAL REPORT ON FORM 20-F

DIVIDEND DISTRIBUTION PROPOSAL

Philip Morris International Presents at 2026 CAGNY Conference; Reaffirms 2026 Full-Year Forecast

$PM
$RACE
Insider Trading

$PM
$RACE
SEC Filings

Chairman Calantzopoulos Andre was granted 40,052 shares, increasing direct ownership by 7% to 602,403 units (SEC Form 4)

Group Controller Dobrowolski Reginaldo was granted 6,538 shares, increasing direct ownership by 28% to 26,392 units (SEC Form 4)

Group CEO PMI Olczak Jacek was granted 171,039 shares, increasing direct ownership by 31% to 718,465 units (SEC Form 4)

SEC Form 6-K filed by Ferrari N.V.

SEC Form 20-F filed by Ferrari N.V.

SEC Form 6-K filed by Ferrari N.V.

$PM
$RACE
Analyst Ratings

Ferrari upgraded by Citigroup

Philip Morris International downgraded by Jefferies with a new price target

Ferrari downgraded by HSBC Securities

$PM
$RACE
Financials

DIVIDEND DISTRIBUTION PROPOSAL

Philip Morris International Presents at 2026 CAGNY Conference; Reaffirms 2026 Full-Year Forecast

Philip Morris International Reports 2025 Fourth-Quarter & Full-Year Results

$PM
$RACE
Leadership Updates

Philip Morris International Opens Dialogue on the Future of Human Cognition as a Defining Frontier in the Age of AI

Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation

Philip Morris International Names New External Affairs Leader

$PM
$RACE
Large Ownership Changes

SEC Form SC 13G/A filed by Ferrari N.V. (Amendment)

SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

FERRARI RENEWS ITS PARTNERSHIP WITH PHILIP MORRIS INTERNATIONAL

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $PM$RACE

FERRARI RENEWS ITS PARTNERSHIP WITH PHILIP MORRIS INTERNATIONAL

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $PM$RACE

$PM$RACE Press Releases

FERRARI RELEASES ITS 2025 ANNUAL REPORT AND FILES ANNUAL REPORT ON FORM 20-F

DIVIDEND DISTRIBUTION PROPOSAL

Philip Morris International Presents at 2026 CAGNY Conference; Reaffirms 2026 Full-Year Forecast

$PM$RACE Insider Trading

$PM$RACE SEC Filings

Chairman Calantzopoulos Andre was granted 40,052 shares, increasing direct ownership by 7% to 602,403 units (SEC Form 4)

Group Controller Dobrowolski Reginaldo was granted 6,538 shares, increasing direct ownership by 28% to 26,392 units (SEC Form 4)

Group CEO PMI Olczak Jacek was granted 171,039 shares, increasing direct ownership by 31% to 718,465 units (SEC Form 4)

SEC Form 6-K filed by Ferrari N.V.

SEC Form 20-F filed by Ferrari N.V.

SEC Form 6-K filed by Ferrari N.V.

$PM$RACE Analyst Ratings

Ferrari upgraded by Citigroup

Philip Morris International downgraded by Jefferies with a new price target

Ferrari downgraded by HSBC Securities

$PM$RACE Financials

DIVIDEND DISTRIBUTION PROPOSAL

Philip Morris International Presents at 2026 CAGNY Conference; Reaffirms 2026 Full-Year Forecast

Philip Morris International Reports 2025 Fourth-Quarter & Full-Year Results

$PM$RACE Leadership Updates

Philip Morris International Opens Dialogue on the Future of Human Cognition as a Defining Frontier in the Age of AI

Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation

Philip Morris International Names New External Affairs Leader

$PM$RACE Large Ownership Changes

SEC Form SC 13G/A filed by Ferrari N.V. (Amendment)

SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

Recent Analyst Ratings for
$PM
$RACE

Recent Analyst Ratings for
$PM
$RACE

$PM
$RACE
Press Releases

$PM
$RACE
Insider Trading

$PM
$RACE
SEC Filings

$PM
$RACE
Analyst Ratings

$PM
$RACE
Financials

$PM
$RACE
Leadership Updates

$PM
$RACE
Large Ownership Changes